Literature DB >> 20170672

Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Fernando Berrendero1, Patricia Robledo, José Manuel Trigo, Elena Martín-García, Rafael Maldonado.   

Abstract

Nicotine is the primary component of tobacco that maintains the smoking habit and develops addiction. The adaptive changes of nicotinic acetylcholine receptors produced by repeated exposure to nicotine play a crucial role in the establishment of dependence. However, other neurochemical systems also participate in the addictive effects of nicotine including glutamate, cannabinoids, GABA and opioids. This review will cover the involvement of these neurotransmitters in nicotine addictive properties, with a special emphasis on the endogenous opioid system. Thus, endogenous enkephalins and beta-endorphins acting on mu-opioid receptors are involved in nicotine-rewarding effects, whereas opioid peptides derived from prodynorphin participate in nicotine aversive responses. An up-regulation of mu-opioid receptors has been reported after chronic nicotine treatment that could counteract the development of nicotine tolerance, whereas the down-regulation induced on kappa-opioid receptors seems to facilitate nicotine tolerance. Endogenous enkephalins acting on mu-opioid receptors also play a role in the development of physical dependence to nicotine. In agreement with these actions of the endogenous opioid system, the opioid antagonist naltrexone has shown to be effective for smoking cessation in certain sub-populations of smokers.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170672      PMCID: PMC2908214          DOI: 10.1016/j.neubiorev.2010.02.006

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  194 in total

Review 1.  Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.

Authors:  Ko Hasebe; Koji Kawai; Tomohiko Suzuki; Kuniaki Kawamura; Toshiaki Tanaka; Minoru Narita; Hiroshi Nagase; Tsutomu Suzuki
Journal:  Ann N Y Acad Sci       Date:  2004-10       Impact factor: 5.691

Review 2.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

3.  Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal.

Authors:  Gökhan Göktalay; Sinan Cavun; Mark C Levendusky; Jonathan R Hamilton; William R Millington
Journal:  Eur J Pharmacol       Date:  2005-12-20       Impact factor: 4.432

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Naltrexone augments the effects of nicotine replacement therapy in female smokers.

Authors:  Joanne A Byars; Kimberly Frost-Pineda; William S Jacobs; Mark S Gold
Journal:  J Addict Dis       Date:  2005

6.  Nicotine maintains robust self-administration in rats on a limited-access schedule.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence.

Authors:  Matthias E Liechti; Loic Lhuillier; Klemens Kaupmann; Athina Markou
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

8.  Evidence for addiction-like behavior in the rat.

Authors:  Véronique Deroche-Gamonet; David Belin; Pier Vincenzo Piazza
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

9.  Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice.

Authors:  Ramiro Salas; Renea Sturm; Jim Boulter; Mariella De Biasi
Journal:  J Neurosci       Date:  2009-03-11       Impact factor: 6.167

10.  ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

Authors:  C Mollereau; M Parmentier; P Mailleux; J L Butour; C Moisand; P Chalon; D Caput; G Vassart; J C Meunier
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

View more
  51 in total

1.  Predictors of Tobacco Use Among New York State Addiction Treatment Patients.

Authors:  Joseph Guydish; Jiang Yu; Thao Le; Anna Pagano; Kevin Delucchi
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

2.  The prohormone proenkephalin possesses differential conformational features of subdomains revealed by rapid H-D exchange mass spectrometry.

Authors:  Weiya D Lu; Tong Liu; Sheng Li; Virgil L Woods; Vivian Hook
Journal:  Protein Sci       Date:  2012-01-04       Impact factor: 6.725

3.  Influence of δ-opioid receptors in the behavioral effects of nicotine.

Authors:  Fernando Berrendero; Ainhoa Plaza-Zabala; Lola Galeote; África Flores; S Andreea Bura; Brigitte L Kieffer; Rafael Maldonado
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

4.  Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Authors:  Samuel R Chamberlain; Karin Mogg; Brendan P Bradley; Annelize Koch; Chris M Dodds; Wenli X Tao; Kay Maltby; Bhopinder Sarai; Antonella Napolitano; Duncan B Richards; Edward T Bullmore; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

5.  Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.

Authors:  Jeffrey S Smith; Abigail G Schindler; Emma Martinelli; Richard M Gustin; Michael R Bruchas; Charles Chavkin
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

Review 6.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

7.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

8.  Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Authors:  Andrés P Varani; Ester Aso; Lirane Machado Moutinho; Rafael Maldonado; Graciela N Balerio
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

9.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

10.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Authors:  Funda Akkus; Simon M Ametamey; Valerie Treyer; Cyrill Burger; Anass Johayem; Daniel Umbricht; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.